| NCT ID | NCT07543159 |
| Status | Recruiting |
| Phase | — |
| Sponsor | North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists |
| Condition | Cancer Risk |
| Study Type | OBSERVATIONAL |
| Enrollment | 900,000 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2035-10-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900,000 participants in total. It began in 2025-12-23 with a primary completion date of 2035-10-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.
Eligibility Criteria
Inclusion Criteria: 1. Subjects must be at least 18 years of age 2. Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent 3. Subjects may or may not have active disease at the time of enrollment 4. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors. Exclusion Criteria: 4\) Subjects not meeting the inclusion criteria Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07543159 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07543159 currently recruiting?
Yes, NCT07543159 is actively recruiting participants. Contact the research team at Biobanking@nycancer.com for enrollment information.
Where is the NCT07543159 trial being conducted?
This trial is being conducted at Shirley, United States.
Who is sponsoring the NCT07543159 clinical trial?
NCT07543159 is sponsored by North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists. The trial plans to enroll 900,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.